🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Genetic loss of the ubiquitin ligase RNF126, an AID interacting partner and modifier, affects strand targeting during somatic hypermutation of antibody genes biorxiv.org/cgi/content/sh… #bioRxiv

New findings by Dr. Peter Glazer .@Glazerlab in @nresearchnews identified, in a novel way, how abnormal cell metabolism impacts #DNA repair. Smilow Cancer Hospital Yale School of Medicine Yale New Haven Hosp yalecancercenter.org/news-article/2…

(1/x) Excited 2announce our most recent work on oncometabolites+DNA repair is out @nature today. A wonderful collaborative effort led by the Glazer & Bindra labs+many collaborators...here's the scoop Yale Cancer Center Yale Radiation Oncology Residency @parkersulkowski Peter Glazer rdcu.be/b4BiY

Research published in Nature describes how altered cancer metabolism suppresses DNA repair via the production of an oncometabolite. go.nature.com/3cAhyfp

News & Views: A study in Nature reveals how several metabolites that accumulate to high levels in tumour cells suppress DNA repair, revealing a direct link between altered metabolism and genome instability caused by DNA damage. go.nature.com/30gnK9R

Saliva viral load is a dynamic unifying correlate of COVID-19 severity and mortality medrxiv.org/cgi/content/sh… #medRxiv

New research led by Nicholas Economos, MD, PhD and Peter Glazer in Nucleic Acids Research Nucleic Acids Res reveals the creation of a next-generation #CRISPR precision tool to aid gene editing. Smilow Cancer Hospital Yale School of Medicine Yale New Haven Hosp yalecancercenter.org/news-article/y…

Researchers from Yale Cancer Center, including ASGCT Associate Member Nicholas Economos, MD, PhD & Member Peter M. Glazer, PhD, MD, created a next-generation #CRISPR-Cas9 “off-switch” and precision tool to aid safe #geneediting therapeutics in patients. bit.ly/3vQlzto

#SCGE researchers Peter Glazer and Nicholas Economos, MD, PhD of Yale Cancer Center shares insights on their work involving a new precision tool to aid #geneediting and #CRISPR 🧬 medicine.yale.edu/news-article/y…

SCITECH | A new study published at Yale’s Glazer Lab has important implications for enhancing the accuracy and efficacy of CRISPR-Cas9 gene editing. bit.ly/3CyFT3G

Yale Cancer Center Scientists Create Next-Generation CRISPR Tool to Aid Gene Editing Yale Cancer Center #oncology #MedTwitter ow.ly/N7s250ImQyM

An 'antispacer' is an guide RNA spacer-targeted peptide nucleic acid used for #GeneRegulation of #CRISPR systems. Read more about this technique in Peter Glazer's publication: pubmed.ncbi.nlm.nih.gov/35235944/ #SCGE 🧬 Yale School of Medicine

Postdoctoral trainees are major drivers of research and innovation. It's been a pleasure to work with Upasna Thapar and Nick Economos, in a great collaboration with Peter Glazer. Please read our publication here: doi.org/10.1016/j.jbc.… #PostdocAppreciationWeek Karras Lab

We are pleased to announce the six emerging startups chosen to participate in the #MassBioDrive Fall 2022 Cohort: AdductNE, HDAX Therapeutics, Hybridex Biosciences, Jenthera Therapeutics Inc., Orion, and pacDNA massbio.org/innovation-ser…

We’re proud to announce that Hybridex has been chosen to participate in MassBio’s #MassBioDrive fall 2022 cohort! massbio.org/news/recent-ne… (1/3)